SiRNA delivery by stimuli-sensitive nanocarriers

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4566-4573

  Salzano, Giuseppina ^a   Costa, Daniel F ^a,c   Torchilin, Vladimir P ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; SMALL INTERFERING RNA;

DRUG DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; IN VITRO STUDY; MAGNETIC FIELD; MAGNETISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION POTENTIAL; PH; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; NANOPARTICLES; NUCLEIC ACIDS; RNA, SMALL INTERFERING;

EID: 84946718729     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282131151013190410     Document Type: Review

References (68)

1. [1] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-60.
2. [2] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006; 58: 1532-55.
3. [3] Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery ofcancer drugs. Annu Rev Med 2012; 63: 185-98.
4. [4] Dicheva BM, Koning GA. Targeted thermosensitive liposomes: anattractive novel approach for increased drug delivery to solid tumors. Expert Opin Drug Deliv 2014; 11: 83-100.
5. [5] Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulatesystems for drug delivery. Nat Rev Drug Discov 2014; 13: 813-27.
6. [6] Sawant RR, Torchilin VP. Multifunctional nanocarriers and intra-cellular drug delivery. Curr Opin Solid State Mater Sci 2012; 16: 269-75.
7. [7] Torchilin V. Multifunctional and stimuli-sensitive pharmaceuticalnanocarriers. Eur J Pharm Biopharm 2009; 71: 431-44.
8. [8] Ringsdorf H. Structure and properties of pharmacologically activepolymers. J Polym Sci Polym Sympos 1975; 51: 135-53.
9. [9] Guo S, Huang L. Nanoparticles escaping RES and endosome:challenges for siRNA delivery for cancer therapy. J Nanomater 2011; 2011: 74 2895.
10. [10] Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilizedshort interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005; 41: 1349-56.
11. [11] Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistentin vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-7.
12. [12] Niu XY, Peng ZL, Duan WQ, Wang H, Wang P. Inhibition of HPV16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006; 16: 743-51.
13. [13] Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006; 12: 4916-24.
14. [14] Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA Therapeu-tics: Barriers and Carriers. AAPS J 2010; 12: 492-503.
15. [15] Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles fordelivery of drugs and siRNA. Front Pharmacol 2014; 5: 77.
16. [16] Midoux P, Pichon C, Yaouanc JJ, Jaffrès PA. Chemical vectors forgene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009; 157: 166-78.
17. [17] Kilk K, El-Andaloussi S, Järver P, et al. Evaluation of transportan10 in PEI mediated plasmid delivery assay. J Control Release 2005; 103: 511-23.
18. [18] Chu D, Xu W, Pan R, Ding Y, Sui W, Chen P. Rational modifica-tion of oligoarginine for highly efficient siRNA delivery: structure activity relationship and mechanism of intracellular trafficking of siRNA. Nanomedicine 2014 Sep 2; Epub ahead of print. Available at: (nanomedjournal.com/article/S1549-9634(14)00430-4/abstract).
19. [19] Parhiz H, Hashemi M, Hatefi A, Shier WT, Amel Farzad S, Ramezani M. Arginine-rich hydrophobic polyethylenimine: potent agent with simple components for nucleic acid delivery. Int J Biol Macromol 2013; 60: 18-27.
20. [20] Wang DA, Narang AS, Kotb M, et al. Novel branchedpoly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 2002; 3: 1197-207.
21. [21] Chen L, Tian H, Chen J, Chen X, Huang Y, Jing X. Multi-armedpoly(L-glutamic acid)-graft oligoethylenimine copolymers as efficient nonviral gene delivery vectors. J Gene Med 2010; 12: 64-76.
22. [22] Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C,Torchilin VP. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) 2012; 7: 65-78.
23. [23] Farhood H, Serbina N, Huang L. The role of dioleoyl phosphati-dylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995; 1235: 289-95.
24. [24] Essex S, Navarro G, Sabhachandani P, et al. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Ther 2014 Oct 30; Epub ahead of print. Available at: (nature.com/gt/journal/vaop/ncurrent/full/gt201497a.html).
25. [25] Xie Y, Qiao H, Su Z, Chen M, Ping Q, Sun M. PEGylated car-boxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. Biomaterials 2014; 35: 7978-91.
26. [26] Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfec-tion of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006; 27: 3147-53.
27. [27] Pedraza CE, Bassett DC, McKee MD, Nelea V, Gbureck U, Bar-ralet JE. The importance of particle size and DNA condensation salt for calcium phosphate nanoparticle transfection. Biomaterials 2008; 29: 3384-92.
28. [28] Graham FL, AJVd Erb. A new technique for the assay of infectiv-ity of human adenovirus 5 DNA. Virology 1973; 52: 456-67.
29. [29] Kalita SJ, Bhardwaj A, Bhatt HA. Nanocrystalline calcium phos-phate ceramics in biomedical engineering. Mater Sci Eng C Mater Biol Appl 2007; 27: 441-49.
30. [30] Cheng X, Kuhn L. Chemotherapy drug delivery from calciumphosphate nanoparticles. Int J Nanomed 2007; 2: 667-74.
31. [31] Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phos-phate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharm 2005; 288: 157-68.
32. [32] Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradablecalcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010; 142: 416-21.
33. [33] Neumann S, Kovtun A, Dietzel ID, Epple M, Heumann R. The useof size-defined DNA-functionalized calcium phosphate nanoparticles to minimise intracellular calcium disturbance during transfection. Biomaterials 2009; 30: 6794-802.
34. [34] Xie Y, Qiao H, Su Z, Chen M, Ping Q, Sun M. PEGylated car-boxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. Biomaterials 2014; 35: 7978-91.
35. [35] Carmona S, Jorgensen MR, Kolli S, et al. Controlling HBV replica-tion in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2009; 6: 706-17.
36. [36] Auguste DT, Furman K, Wong A, et al. Triggered release ofsiRNA from poly(ethylene glycol) protected, pH-dependent liposomes. J Control Release 2008; 130: 266-74.
37. [37] Sies H. Glutathione and its role in cellular functions. Free RadicBiol Med 1999; 27: 916-21.
38. [38] Jones DP, Mody VC Jr, Carlson JL, Lynn MJ, Sternberg P Jr. Re-dox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic Biol Med 2002; 33: 1290-300.
39. [39] Kim SH, Jeong JH, Kim TI, Kim SW, Bull DA. VEGF siRNAdelivery system using arginine grafted bioreducible poly(disulfide amine). Mol Pharm 2009; 6: 718-26.
40. [40] Vader P, van der Aa LJ, Engbersen JF, Storm G, Schiffelers RM.Disulfide-based poly(amido amine)s for siRNA delivery: effects of structure on siRNA complexation, cellular uptake, gene silencing and toxicity. Pharm Res 2011; 28: 1013-22.
41. [41] Li J, Cheng D, Yin T, et al. Copolymer of poly(ethylene glycol)and poly(L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery. Nanoscale 2014; 6: 1732-40.
42. [42] Musacchio T, Vaze O, D'Souza G, Torchilin VP. Effective stabili-zation and delivery of siRNA: reversible siRNA phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem 2010; 21: 1530-6.Salzano et al.
43. [43] Basel MT1, Shrestha TB, Troyer DL, Bossmann SH. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano 2011; 5: 2162-75.
44. [44] Pak CC, Ali S, Janoff AS, Meers P. Triggerable liposomal fusionby enzyme cleavage of a novel peptide-lipid conjugate. Biochim Biophys Acta 1998; 1372: 13-27.
45. [45] Pak CC, Erukulla RK, Ahl PL, Janoff ASP. Elastase activatedliposomal delivery to nucleated cells. Biochim Biophys Acta 1999; 1419: 111-26.
46. [46] Hatakeyama H, Akita H, Kogure K, et al. Development of a novelsystemic gene delivery system for cancer therapy with a tumorspecific cleavable PEG-lipid. Gene Ther 2007; 14: 68-77.
47. [47] Mansour AM, Drevs J, Esser N, et al. A new approach for thetreatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003; 63: 4062-6.
48. [48] Yingyuad P, Mével M, Prata C, Kontogiorgis C, Thanou M, Miller AD. Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. J RNAi Gene Silencing 2014; 10: 490-9.
49. [49] Zhu L, Perche F, Wang T, Torchilin VP. Matrix metalloproteinase2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials 2014; 35: 4213-22.
50. [50] Shubayev VI, Pisanic TR 2nd, Jin S. Magnetic nanoparticles fortheragnostics. Adv Drug Deliv Rev 2009; 61: 467-77.
51. [51] Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treat-ment with magnetic drug targeting. Cancer Res 2000; 60: 6641-8.
52. [52] Mosbach K, Schröder U. Preparation and application of magneticpolymers for targeting of drugs. FEBS Lett 1979; 102: 112-6.
53. [53] Wahajuddin1, Arora S. Superparamagnetic iron oxide nanoparti-cles: magnetic nanoplatforms as drug carriers. Int J Nanomed 2012; 7: 3445-71.
54. [54] Zhu L, Huo Z, Wang L, Tong X, Xiao Y, Ni K. Targeted deliveryof methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm 2009; 370: 136-43.
55. [55] Wang FH, Kim DK, Yoshitake T, et al. Diffusion and clearance ofsuperparamagnetic iron oxide nanoparticles infused into the rat striatum studied by MRI and histochemical techniques. Nanotechnology 2011; 22: 015103.
56. [56] Ma X, Gong A, Chen B, et al. Exploring a new SPION-based MRIcontrast agent with excellent water-dispersibility, high specificity to cancer cells and strong MR imaging efficacy. Colloids Surf B Biointerfaces 2014; 126C: 44-49.
57. [57] Lee JH1, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-onetarget-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 2009; 48: 4174-9.
58. [58] Shen M, Gong F, Pang P, et al. An MRI-visible non-viral vector fortargeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomed 2012; 7: 3319-32.
59. [59] Wu C, Gong F, Pang P, et al. An RGD-modified MRI-visible po-lymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice. PLoS One 2013; 8: e66416.
60. [60] Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, TorchilinVP. Polymeric micelles containing reversibly phospholipidmodified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. Cancer Lett 2014; 343: 224-31.
61. [61] Hu Q, Li W, Hu X, et al. Synergistic treatment of ovarian cancerby co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 2012; 33: 6580-91.
62. [62] Chen W, Yuan Y, Cheng D, Chen J, Wang L, Shuai X. Co-deliveryof doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy. Small 2014; 10: 2678-87.
63. [63] Li D, Tang X, Pulli B, et al. Theranostic nanoparticles based onbioreducible polyethylenimine-coated iron oxide for reductionresponsive gene delivery and magnetic resonance imaging. Int J Nanomed 2014; 9: 3347-61.
64. [64] Chertok B, David AE, Yang VC. Polyethyleneimine-modified ironoxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 2010; 31: 6317-24.
65. [65] Veiseh O, Kievit FM, Liu V, et al. In vivo safety evaluation ofpolyarginine coated magnetic nanovectors. Mol Pharm 2013; 10: 4099-106.
66. [66] Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes andhepatic stellate cells by bioconjugation. Bioconjug Chem 2010; 21: 2119-27.
67. [67] Sawant RM, Hurley JP, Salmaso S, et al. "SMART" drug deliverysystems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 2006; 17: 943-9.
68. [68] Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipaseA(2) triggered siRNA release: Preparation and in vitro test. Int J Pharm 2007; 331: 160-6.